复发/难治性边缘区淋巴瘤的管理：聚焦于伊布替尼
Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib.
作者信息
Denlinger Nathan M, Epperla Narendranath, William Basem M
机构信息
Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center (OSUCCC-James), The Ohio State University, Columbus, OH, USA.
出版信息
Cancer Manag Res. 2018 Mar 27;10:615-624. doi: 10.2147/CMAR.S133291. eCollection 2018.
Abstract
Marginal zone lymphomas (MZLs) consist of a diverse family of malignancies, which are derived from B-cells. The disease subtypes are recognized extranodal, nodal, and splenic MZLs. The disease characteristics, clinical course, and treatment vary considerably based on the site of involvement. In 2017, the US Food and Drug Administration approved ibrutinib, a first in class Bruton's tyrosine kinase inhibitor that revolutionized the care of chronic lymphocytic leukemia patients; for, the treatment of relapsed/refractory MZL based on pivotal open-label Phase II trial demonstrated an overall response rate of 48%, with a complete response rate of 3%, median progression-free survival of 14.2 months, and median overall survival not yet reached at a median follow-up of 19.4 months. In this review, we aim to summarize the current conundrums in the management of MZL and the evolving role of ibrutinib in the treatment of MZL.
摘要
边缘区淋巴瘤（MZL）由多种源自B细胞的恶性肿瘤组成。该疾病亚型包括结外、结内和脾MZL。根据受累部位的不同，疾病特征、临床病程和治疗方法差异很大。2017年，美国食品药品监督管理局批准了伊布替尼，这是首个获批的布鲁顿酪氨酸激酶抑制剂，它彻底改变了慢性淋巴细胞白血病患者的治疗方式；基于关键的开放标签II期试验，伊布替尼用于治疗复发/难治性MZL的总体缓解率为48%，完全缓解率为3%，中位无进展生存期为14.2个月，在中位随访19.4个月时中位总生存期尚未达到。在本综述中，我们旨在总结MZL管理中的当前难题以及伊布替尼在MZL治疗中不断演变的作用。
相似文献
1
Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib.复发/难治性边缘区淋巴瘤的管理：聚焦于伊布替尼
Cancer Manag Res. 2018 Mar 27;10:615-624. doi: 10.2147/CMAR.S133291. eCollection 2018.
2
Marginal Zone Lymphoma: Clinicopathologic Variations and Approaches to Therapy.边缘区淋巴瘤：临床病理变异与治疗方法。
Curr Oncol Rep. 2018 Mar 23;20(4):33. doi: 10.1007/s11912-018-0687-9.
3
Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.利妥昔单抗：用于非霍奇金淋巴瘤和慢性淋巴细胞白血病的综述
Drugs. 2003;63(8):803-43. doi: 10.2165/00003495-200363080-00005.
4
A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.新型布鲁顿酪氨酸激酶抑制剂依鲁替尼的综述
J Oncol Pharm Pract. 2016 Feb;22(1):92-104. doi: 10.1177/1078155214561281. Epub 2014 Nov 25.
5
Zanubrutinib in lymphoproliferative disorders: a comprehensive review.泽布替尼治疗淋巴增殖性疾病：全面综述
Ther Adv Hematol. 2022 May 27;13:20406207221093980. doi: 10.1177/20406207221093980. eCollection 2022.
6
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.在复发/难治性边缘区淋巴瘤中使用依鲁替尼靶向布鲁顿酪氨酸激酶。
Blood. 2017 Apr 20;129(16):2224-2232. doi: 10.1182/blood-2016-10-747345. Epub 2017 Feb 6.
7
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.伊布替尼治疗一线和复发/难治性慢性淋巴细胞白血病：关键性 Ib/II 期 PCYC-1102 研究的最终分析。
Clin Cancer Res. 2020 Aug 1;26(15):3918-3927. doi: 10.1158/1078-0432.CCR-19-2856. Epub 2020 Mar 24.
8
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis.复发/难治性边缘区淋巴瘤中依鲁替尼的持久反应：长期随访和生物标志物分析
Blood Adv. 2020 Nov 24;4(22):5773-5784. doi: 10.1182/bloodadvances.2020003121.
9
Primary nodal marginal zone lymphomas of splenic and MALT type.脾脏和MALT型原发性淋巴结边缘区淋巴瘤。
Am J Surg Pathol. 1999 Jan;23(1):59-68. doi: 10.1097/00000478-199901000-00006.
10
Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group.依维莫司治疗复发/难治性边缘区 B 细胞淋巴瘤的临床活性：国际结外淋巴瘤研究组的 II 期研究结果。
Br J Haematol. 2014 Jul;166(1):69-76. doi: 10.1111/bjh.12845. Epub 2014 Mar 27.
引用本文的文献
1
Delphi consensus recommendations on treatment for advanced-stage marginal zone lymphoma in South Korea.韩国晚期边缘区淋巴瘤治疗的德尔菲共识建议。
Ann Hematol. 2024 Sep;103(9):3615-3625. doi: 10.1007/s00277-024-05907-5. Epub 2024 Aug 6.
2
Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study.在复发/难治性边缘区淋巴瘤中，zanubrutinib 的安全性和有效性：MAGNOLIA 研究的最终分析。
Blood Adv. 2023 Nov 28;7(22):6801-6811. doi: 10.1182/bloodadvances.2023010668.
3
Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study.奥妥珠单抗对比利妥昔单抗用于既往未治疗的惰性非霍奇金淋巴瘤的免疫化疗：GALLIUM研究的最终结果
Hemasphere. 2023 Jun 30;7(7):e919. doi: 10.1097/HS9.0000000000000919. eCollection 2023 Jul.
4
Estimating the Burden of Illness of Relapsed Follicular Lymphoma and Marginal Zone Lymphoma in Ontario, Canada.估算加拿大安大略省复发性滤泡性淋巴瘤和边缘区淋巴瘤的疾病负担。
Curr Oncol. 2023 Apr 30;30(5):4663-4676. doi: 10.3390/curroncol30050352.
5
Design of Novel Phosphatidylinositol 3-Kinase Inhibitors for Non-Hodgkin's Lymphoma: Molecular Docking, Molecular Dynamics, and Density Functional Theory Studies on Gold Nanoparticles.新型磷脂酰肌醇 3-激酶抑制剂用于非霍奇金淋巴瘤的设计：基于金纳米粒子的分子对接、分子动力学和密度泛函理论研究。
Molecules. 2023 Mar 1;28(5):2289. doi: 10.3390/molecules28052289.
6
Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma.泽布替尼单药治疗复发/难治性惰性非霍奇金淋巴瘤。
Blood Adv. 2022 Jun 14;6(11):3472-3479. doi: 10.1182/bloodadvances.2021006083.
7
Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial.在随机化GALLIUM试验中，对先前未经治疗的边缘区淋巴瘤患者使用奥妥珠单抗或利妥昔单抗进行免疫化疗及维持治疗。
Hemasphere. 2022 Feb 24;6(3):e699. doi: 10.1097/HS9.0000000000000699. eCollection 2022 Mar.
8
Current Status of the Spectrum and Therapeutics of -Negative Mucosa-Associated Lymphoid Tissue Lymphoma.阴性黏膜相关淋巴组织淋巴瘤的谱系与治疗现状
Cancers (Basel). 2022 Feb 16;14(4):1005. doi: 10.3390/cancers14041005.
9
The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma.MAGNOLIA 试验：新一代布鲁顿酪氨酸激酶抑制剂泽布替尼在复发/难治性边缘区淋巴瘤中表现出安全性和疗效。
Clin Cancer Res. 2021 Dec 1;27(23):6323-6332. doi: 10.1158/1078-0432.CCR-21-1704. Epub 2021 Sep 15.
10
Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors.癌症治疗的血管影响：以 BTK（布鲁顿酪氨酸激酶）抑制剂为例。
Circ Res. 2021 Jun 11;128(12):1973-1987. doi: 10.1161/CIRCRESAHA.121.318259. Epub 2021 Jun 10.
本文引用的文献
1
High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO.大剂量化疗和自体造血干细胞移植治疗边缘区淋巴瘤：EBMT 淋巴瘤工作组和 FIL-GITMO 的回顾性研究。
Br J Haematol. 2018 Sep;182(6):807-815. doi: 10.1111/bjh.15454. Epub 2018 Jul 9.
2
Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.单药伊布替尼治疗复发或难治性滤泡性淋巴瘤：一项 2 期联盟试验。
Blood. 2018 Jan 11;131(2):182-190. doi: 10.1182/blood-2017-09-804641. Epub 2017 Oct 26.
3
A MALT lymphoma prognostic index.MALT 淋巴瘤预后指数。
Blood. 2017 Sep 21;130(12):1409-1417. doi: 10.1182/blood-2017-03-771915. Epub 2017 Jul 18.
4
Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy.IELSG-19 随机试验的最终结果：利妥昔单抗联合苯丁酸氮芥与苯丁酸氮芥或利妥昔单抗单药治疗黏膜相关淋巴组织淋巴瘤的无事件和无进展生存得到改善。
J Clin Oncol. 2017 Jun 10;35(17):1905-1912. doi: 10.1200/JCO.2016.70.6994. Epub 2017 Mar 29.
5
Treatment of splenic marginal zone lymphoma.脾边缘区淋巴瘤的治疗
Best Pract Res Clin Haematol. 2017 Mar-Jun;30(1-2):139-148. doi: 10.1016/j.beha.2016.07.004. Epub 2016 Nov 4.
6
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.在复发/难治性边缘区淋巴瘤中使用依鲁替尼靶向布鲁顿酪氨酸激酶。
Blood. 2017 Apr 20;129(16):2224-2232. doi: 10.1182/blood-2016-10-747345. Epub 2017 Feb 6.
7
Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era.脾边缘区淋巴瘤：利妥昔单抗时代治疗的64例患者疗效优异。
Hematology. 2017 Aug;22(7):405-411. doi: 10.1080/10245332.2017.1279842. Epub 2017 Jan 20.
8
A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma.利妥昔单抗联合来那度胺治疗黏膜相关淋巴组织淋巴瘤的2期研究。
Blood. 2017 Jan 19;129(3):383-385. doi: 10.1182/blood-2016-06-720599. Epub 2016 Nov 22.
9
The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma.苯达莫司汀联合利妥昔单抗方案对原发性淋巴结边缘区B细胞淋巴瘤有效。
Hematol Oncol. 2017 Dec;35(4):536-541. doi: 10.1002/hon.2334. Epub 2016 Jul 22.
10
Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era.双机构结节性边缘区淋巴瘤的经验显示，在利妥昔单抗时代有出色的长期预后。
Br J Haematol. 2016 Oct;175(2):275-280. doi: 10.1111/bjh.14228. Epub 2016 Jul 22.
Zotero 插件